Molecularly Targeted Therapies in Breast Cancer: A Traditional Review

Globally, breast cancer stands as the most frequently diagnosed

cancer among women, with its incidence continually on the rise.

Conventional treatment methods for breast cancer have inherent

limitations. Consequently, the development of innovative treatment

approaches is imperative. Among these, targeted therapy strategies

have emerged as a critical point in contemporary clinical research,

significantly diversifying the treatment landscape for breast cancer in

recent years. The goals of these new treatment strategies are evolving

toward a future that can overcome the limitations of traditional

treatment methods, protect patients from side effects, and improve

patients’ survival rates and life quality. Nowadays, therapeutic

agents that bind to preferred targets are used based specifically on

various subtypes of breast cancer. The FDA-approved targeted

therapeutic agents—such as monoclonal antibodies, gene therapies,

immunotherapeutic cancer vaccines, and small molecule inhibitors,

are reviewed in this article.